Literature DB >> 11589718

Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women.

L Rejnmark1, P Vestergaard, L Heickendorff, F Andreasen, L Mosekilde.   

Abstract

BACKGROUND: Thiazide diuretics (TD) reduce urinary calcium, bone loss and fracture risk. Loop diuretics (LD) may have opposite effects. These effects could depend on induced rhythmic changes in bone and calcium homeostasis.
DESIGN: After a run-in period of 7 days, we studied (in a factorial design) the diurnal rhythms of plasma levels of calcium, phosphate, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D and osteocalcin, as well as renal excretions rates of calcium, phosphate, and cross-linked N-terminal telopeptide of type 1 collagen (NTx) in 50 postmenopausal women randomized to treatment with either a thiazide diuretic (TD; bendroflumethiazide, n = 14), a loop diuretic (LD; bumetanide, n = 13), LD plus TD (bendroflumethiazide plus bumetanide, n = 11), or placebo (n = 12).
RESULTS: In all four groups, all measured quantities showed a diurnal variation. LD caused a steep increase, with a subsequent decrease, in urinary calcium and plasma PTH. The mean 24 h plasma PTH concentration was increased (8.5 +/- 0.9 mmol L-1) compared with placebo (4.4 +/- 0.4 mmol L-1), whereas net 24 h renal calcium excretion did not differ from that of the placebo group due to a rebound hypocalciuria. Compared with placebo, diurnal rhythms of plasma phosphate and osteocalcin were changed with an increase during daytime and a decrease during the night. TD did not alter the diurnal rhythm of any of the measured quantities. However, the 24-h renal calcium excretion decreased, whereas the mean 24-h plasma calcium concentration increased without PTH suppression. LD plus TD caused changes similar to those observed with LD alone.
CONCLUSION: One daily dose of LD increases parathyroid activity with alterations in the diurnal pattern of osteocalcin. This could indicate a potential anabolic effect of LD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589718     DOI: 10.1046/j.1365-2362.2001.00883.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Prabin Thapa; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

Review 2.  The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies.

Authors:  Anne Claire B van Orten-Luiten; André Janse; Rosalie A M Dhonukshe-Rutten; Renger F Witkamp
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923

3.  Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system.

Authors:  Marie-Eve Muller; Valentina Forni Ogna; Marc Maillard; Candice Stoudmann; Carole Zweiacker; Christiane Anex; Grégoire Wuerzner; Michel Burnier; Olivier Bonny
Journal:  Pflugers Arch       Date:  2015-06-20       Impact factor: 3.657

4.  Genetic Ancestry, Skin Reflectance and Pigmentation Genotypes in Association with Serum Vitamin D Metabolite Balance.

Authors:  Robin Taylor Wilson; Alanna N Roff; P Jenny Dai; Tracey Fortugno; Jonathan Douds; Gang Chen; Gary L Grove; Sheila Ongeri Nikiforova; Jill Barnholtz-Sloan; Tony Frudakis; Vernon M Chinchilli; Terryl J Hartman; Laurence M Demers; Mark D Shriver; Victor A Canfield; Keith C Cheng
Journal:  Horm Mol Biol Clin Investig       Date:  2011-09

5.  Incidence and clinical spectrum of thiazide-associated hypercalcemia.

Authors:  Robert A Wermers; Ann E Kearns; Gregory D Jenkins; L Joseph Melton
Journal:  Am J Med       Date:  2007-04-16       Impact factor: 4.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.